Modified immune cells for severe fungal infections
Part of Infections clinical trials.
This trial tests a new treatment using a patient's own immune cells, called NK cells, that are modified to better fight severe fungal infections that are not responding to standard antifungal medicines. The aim is to see if this approach can help control or clear the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed or highly suspected fungal infection that hasn't improved with standard antifungal treatment.
- Your infection is getting worse despite at least one week of antifungal therapy, as shown by rising biomarkers, positive cultures, or worsening scans.
- You are willing to sign a consent form (or have a family member do it if you're unable).
- You are not living with HIV, are not pregnant or breastfeeding, and agree to use effective contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
This trial tests a new immune cell therapy (engineered NK cells) for people with certain blood cancers like AML, MDS, or CMML that have not responded to standard treatments. The therapy aims to help your immune system attack cancer cells, and is given after a short course of chemotherapy.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Hear when a new Fungal Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.